Abstract:OBJECTIVES:To compare the clinical effect of low molecular weight heparin (LMWH) and regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT) after heart valve replacement. METHODS:Retrospective analysis of clinical data from 60 patients undergoing continuous renal replacement therapy after heart valve replacement in Peking University Shenzhen Hospital from January 2015 to July 2019, including 35 males and 25 females, aged (58.83 ±16.36) years. The patients were divided into a LMWH group and a RCA group according to the anticoagulation regimen, with 30 patients in each group. The 24 h postoperative drainage volume (pericardium, mediastinum), postoperative ventilator use time and ICU stay time, incidence of postoperative respiratory tract bleeding and gastrointestinal bleeding, postoperative skin ecchymosis incidence and mortality between the 2 groups were compared; the thromboplastin time (APTT), fibrinogen (FIB), thrombin time (TT), prothrombin time (PT), international normalized ratio (INR), and PLT between the 2 groups after anticoagulation treatment were compared; the service life of dialysis filters and CRRT time between the 2 groups were compared; and the levels of urea nitrogen and serum creatinine between the 2 groups before and after treatment were also compared. RESULTS:After anticoagulant treatment, the RCA group had less 24 h postoperative drainage volume than the LMWH group, shorter ventilator use time, ICU stay time, and hospitalization days than the LMWH group, and lower respiratory tract bleeding and gastrointestinal bleeding incidence than the LMWH group, with significant differences (all P<0.05); there was no significant difference in the incidence of skin ecchymosis and mortality after treatment between the 2 groups (all P>0.05); there was no significant difference in APTT, FIB, and TT between the 2 groups (all P>0.05); the PT and INR of the RCA group were higher than those in the LMWH group, while the PLT of RCA group was lower than that in the LMWH group, with significant differences (all P<0.05); there was no significant difference in CRRT time between the two groups (P=0.073). After the treatment, there were no significant differences in urea nitrogen and serum creatinine levels between the 2 groups (all P>0.05). CONCLUSIONS:CRRT after cardiac valve replacement with RCA can effectively reduce pericardial and mediastinal drainage, reduce the risk of bleeding, shorten the time of ventilator use and ICU stay, and promote postoperative recovery of patients, which have positive significance for reducing the burden on patients and their families.

Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study

Using nafamostat mesilate anticoagulation for continuous renal replacement therapy in high bleeding risk patients: a systematic review and meta-analysis

Application of regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT) in patients with high risk of bleeding

Regional citrate anticoagulation versus LMWH anticoagulation for CRRT in liver failure patients without increased bleeding risk

Anticoagulation application of Nafamostat Mesylate in critically ill patients received continuous renal replacement therapy and extracorporeal membrane oxygenation

Optimizing Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation: Insights from the ORCA Trial—A Retrospective Study on 10 Years of Practice

Safety and Feasibility of Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy With Calcium‐Containing Solutions: A Randomized Controlled Trial

A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding

Management of regional citrate anticoagulation for continuous renal replacement therapy: guideline recommendations from Chinese emergency medical doctor consensus

Protocolized Regional Citrate Anticoagulation during Continuous Renal Replacement Therapy: A Single Center Experience

Study on the application of a segmented sodium citrate solution anticoagulation strategy in critically ill patients receiving CRRT: a prospective, randomized controlled study

Early experience of using regional citrate anticoagulation for continuous renal replacement therapy in critically ill patients in a resource‐limited setting

Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation

How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes

Comparison of Curative Effect Between Different Anticoagulation Regimens in Continuous Renal Replacement Therapy after Cardiac Valve Replacement.

Clinical application of regional citrate anticoagulation for continuous renal replacement therapy in children with liver injury

Effect of continuous renal replacement therapy with regional citrate anticoagulation on intracerebral hemorrhage complicated with acute renal injury

Analysis of the Extracorporeal Anticoagulation Effect of Modified Citrate Infusion During Continuous Renal Replacement Therapy in Critically Ill Patients

Application of Simplified Regional Citrate Anticoagulation in Hemodialysis Patients with High Risk of Bleeding.

A randomized crossover trial of regional anticoagulation modalities for intermittent hemodialysis

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis